Drug costs

November 10, 2021

The high cost and limited clinical evidence for cell and gene therapies have led U.S. health plans and countries outside the United States to limit access.

September 07, 2021

For an assortment of reasons, the federal government hasn’t taken any action on regulating drug prices, so a handful of states have taken matters into their own hands.

September 07, 2021

A large Netherlands study demonstrated that rituximab biosimilars (R-biosimilars) produced a 43% reduction in annual costs. In addition, three-year overall survival did not differ between diffuse large B-cell lymphoma (DLBCL) and those receiving rituximab, according to the researchers.

August 26, 2021

The new model indicates a small initial impact on new drugs coming to the market, but an impact that grows over time.

August 24, 2021

ICER calculations using real-world data would result in major price cuts of three therapies — Takhzyro, Haegarda, and Cinryze — if they were to meet commonly used cost-effective thresholds.

July 14, 2021

International Generic and Biosimilar Medicines Association recently released the report, "A Vision for the Global Generic and Biosimilar Medicines Industry,” covering the current global Generic and Biosimilar medicine industry, and released a vision of what the market will be in 2030 and how to achieve it.

July 13, 2021

Low prices and some gaming of regulations can drive out competitors and create monopolies that allow generic makers to jack up their prices. Experience has shown that it often takes multiple generics to achieve the promised-for downward pressure on prices.

July 09, 2021

Hospital mergers, drug prices, and non-compete clauses for the rank and file are all targets of President Joe Biden’s pen today as he signed a sweeping executive order instructing federal departments and agencies to reshape what he called “booming” economy by putting workers first, encouraging higher wages and the opportunity for mobility.

June 17, 2021

In this final part of the MHE 2021 Pharmacy Survey, participants share their thoughts on which federal policies they favor as a way to curb drug prices and which policy is more likely to occur this year. MHE's annual pharmacy survey had over 225 respondents.

June 07, 2021

Harvard researchers say, well, maybe.